|3 Months Ended|
Mar. 31, 2021
8. SUBSEQUENT EVENTS
On April 30, 2021, the Company completed its acquisition of Sentry Neuromonitoring, LLC (“Sentry”), one of the largest IONM service providers in Texas, for an aggregate purchase price of $3.5 million. The purchase price to be paid is $1.225 million in cash, payable in installments, and $2.3 million in Assure common stock, payable $1.625 million at closing and $650 thousand into escrow, subject to escrow release. The common stock is subject to 12-month lockup and applicable securities laws and regulations.
On April 15, 2021, the Company appointed a new member to its Board of Directors. In connection with the appointment, the Company
granted 150,000 stock options exercisable to acquire common stock at $1.12 per share for a period of five years.
On May 12, 2021, we filed an application to be listed on the Nasdaq.
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef